| Literature DB >> 34524598 |
Annalisa Schiepatti1,2, Stiliano Maimaris3, Camila de Queiros Mattoso Archela Dos Santos3, Giovanni Rusca3, Stefania Costa3, Federico Biagi3.
Abstract
BACKGROUND: Modalities for the transition to adult care of celiac patients diagnosed during childhood/adolescence and their impact on long-term adherence to a gluten-free diet (GFD-A), quality of life (QOL) and maintenance of follow-up in adulthood are unknown. AIMS: To evaluate whether timing of transition affects long-term GFD-A, QOL, and continuity of follow-up in adulthood and to identify predictors of long-term GFD-A.Entities:
Keywords: Celiac disease; Follow-up; Gluten-free diet; Quality of life; Transition
Mesh:
Year: 2021 PMID: 34524598 PMCID: PMC9287197 DOI: 10.1007/s10620-021-07231-8
Source DB: PubMed Journal: Dig Dis Sci ISSN: 0163-2116 Impact factor: 3.487
Factors associated with GFD adherence first medical consultation
| TOTAL | Poor GFD adherence at first adult medical consultation | Good GFD adherence at first adult medical consultation | OR (95% CI) | ||
|---|---|---|---|---|---|
| Abdominal pain | 39 (23.1%) | 17 (27.4%) | 22 (18.2%) | 0.18 | |
| Anemia | 33 (18.0%) | 10 (16.1%) | 23 (19.0%) | 0.69 | |
| Autoimmunity | 28 (15.3%) | 9 (14.5%) | 19 (15.7%) | 1.00 | |
| Constipation | 9 (4.9%) | 4 (6.5%) | 5 (4.1%) | 0.49 | |
| Dermatitis herpetiformis | 7 (3.8%) | 3 (4.8) | 4 (3.3) | 0.69 | |
| Type of diagnosis | < 0.01 | – | |||
| °Conventional | 169 (92.3%) | 53 (85.5%) | 116 (95.9%) | ||
| °Only clinical | 8 (4.4%) | 7 (11.3%) | 1 (0.8%) | ||
| °Serological (ESPHGAN) | 6 (3.3%) | 2 (3.2%) | 4 (3.3%) | ||
| Diarrhea | 82 (44.8%) | 33 (53.2%) | 49 (40.5%) | 0.12 | |
| Dyspepsia | 30 (16.4%) | 10 (16.1%) | 20 (16.5%) | 1.00 | |
| Failure to thrive | 85 (46.4%) | 23 (37.1%) | 62 (52.1%) | 0.09 | |
| Fever | 3 (1.6%) | 1 (1.6%) | 2 (1.7%) | 1.00 | |
| Gender (F) | 130 (71.0%) | 39 (62.9%) | 91 (75.2%) | 0.09 | |
| HLA * | 0.32 | ||||
| °DQ2 | 25 (80.6%) | 11 (73.3%) | 14 (87.5%) | ||
| °DQ8 | 4 (12.9%) | 3 (20.0%) | 1 (6.2%) | ||
| °DQ2/DQ8 | 1 (3.2%) | 1 (6.7%) | 0 | ||
| °DQ7.5 | 1 (3.2%) | 0 | 1 (6.2%) | ||
| Classical presentation | 125 (68.3%) | 41 (66.1%) | 84 (69.4%) | 0.74 | |
| Weight loss | 27 (14.8%) | 6 (9.87%) | 21 (17.4%) | 0.19 | |
| Family history of CD | 35 (19.1%) | 10 (16.1%) | 25 (20.7%) | 0.55 | |
| Age at diagnosis (years, median, IQR) | 8 (1.00–13.00) | 7.50 (1.00–13.00) | 9.00 (2.00–13.00) | 0.15 | |
| Age at first adult medical consultation (years, median, IQR) | 20 (17.00–25.00) | 21.00 (17.00–26.00) | 20.00 (17.00–23.00) | 0.34 | |
| Pediatric GFD adherence * | < 0.01 | 27.90 (11.18–76.59) | |||
| °Good | 102 (62.2%) | 10 (17.5%) | 92 (86.0%) | ||
| °Poor | 62 (37.8%) | 47 (82.5%) | 15 (14.0%) | ||
| Persisting symptoms at first adult consultation | 74 (40.4%) | 28 (45.2%) | 46 (38.0%) | 0.43 | |
| Persistence of positive EmA* | 34 (31.5%) | 24 (51.1%) | 10 (16.4%) | < 0.01 | 0.19 (0.07–0.49) |
| Persistence of villous atrophy* | 18 (21.2%) | 16 (37.2%) | 2 (4.8%) | < 0.01 | 0.09 (0.01–0.42) |
| Number of adult medical consultations (median, IQR) | 3 (1.00–5.00) | 3 (2.00–5.00) | 2 (1.00–4.00) | 0.08 | |
| Follow-up duration at our center (months, median, IQR) | 12.00 (0.00–60.50) | 14.50 (1.25–70.00) | 10 (0.00–52.00) | 0.08 | |
| Months since last medical consultation (median, IQR) | 80 (23–138) | 106.5 (46.75–149.50) | 67.00 (21.00–129.00) | 0.08 | |
| Lost to follow-up§ | 135 (73.8%) | 49 (79.0%) | 86 (71.1%) | 0.29 | |
| QOL questionnaire score (median, IQR) ** | 167.00 (156.50–178.00) | 162.00 (153.00–173.00) | 169.00 (159.25–179.75) | 0.16 |
*Data not available for some patients: no HLA for 152, no pediatric GFD adherence for 19, no duodenal biopsy for 98, no EmA for 75: percentages were calculated excluding missing data points
**There was also no significant difference for any of the four domains of the questionnaire between groups
§no medical consultations in the last 24 months
Factors associated with long-term GFD adherence during adult follow-up
| Poor long-term GFD adherence | Good long-term GFD adherence | OR (95% CI ) | ||
|---|---|---|---|---|
| Abdominal pain | 11 (26.2%) | 28(19.9%) | 0.40 | |
| Anemia | 5 (11.9%) | 28 (19.9%) | 0.36 | |
| Aphthous stomatitis | 0 | 12 (8.5%) | 0.07 | |
| Asthenia | 5 (11.9%) | 10 (7.1%) | 0.34 | |
| Autoimmunity | 7 (16.7%) | 21 (14.9%) | 0.81 | |
| Constipation | 2 (4.8%) | 7 (5.0%) | 1.00 | |
| Dermatitis herpetiformis | 0 | 7 (5.0%) | 0.35 | |
| Type of diagnosis | 0.52 | |||
| °Conventional | 40 (95.2%) | 129 (91.5%) | ||
| °Only clinical | 2 (4.9%) | 6 (4.3%) | ||
| °Serological (ESPHGAN) | 0 | 6 (4.3%) | ||
| Diarrhea | 18 (42.9%) | 64 (45.4%) | 0.86 | |
| Dyspepsia | 7 (16.7%) | 23 (16.3%) | 1.00 | |
| Failure to thrive | 18 (42.9%) | 66 (47.5%) | 0.73 | |
| Fever | 1 (2.4%) | 2 (1.4%) | 0.55 | |
| Gender (F) | 28 (66.7%) | 102 (72.3%) | 0.35 | |
| HLA* | 0.24 | |||
| °DQ2 | 6 (66.7%) | 19 (86.4%) | ||
| °DQ8 | 2 (22.2%) | 0 | ||
| °DQ2/DQ8 | 1 (11.1%) | 1 (4.5%) | ||
| °DQ7.5 | 0 | 2 (9.1%) | ||
| Classical presentation | 23 (54.8%) | 102 (72.3%) | 0.04 | 2.15 (0.99–4.65) |
| Weight loss | 5 (11.9%) | 22 (15.6%) | 0.63 | |
| Family history of CD | 11 (26.2%) | 24 (17.0%) | 0.19 | |
| Age at diagnosis (years, median, IQR) | 4 (1.0–11.0) | 9 (1.0–13.0) | 0.09 | |
| Good GFD adherence during pediatric follow-up* | 15 (41.7%) | 87 (68.0%) | < 0.01 | 2.95 (1.30–6.85) |
| Age at first adult medical consultation (years, median, IQR) | 20 (17.0–23.75) | 20 (17.0–25.0) | 0.63 | |
| Good GFD adherence at first adult consultation | 19 (45.2%) | 102 (72.3%) | < 0.01 | 3.14 (1.46–6.86) |
| Persistence of positive EmA * | 9 (34.6%) | 25 (30.5%) | 0.81 | |
| Persistence of VA* | 7 (30.4%) | 11 (17.7%) | 0.24 | |
| Number of adult medical consultations (median, IQR) | 2.0 (1.0–4.75) | 3.0 (1.0–5.00) | 0.26 | |
| Duration of disease (months, median, IQR) | 273.0 (218.0–458.0) | 269.0 (166.0–413.0) | 0.19 | |
| F-up duration at our center (months, median, IQR) | 7.50 (0.00–66.25) | 15.00 (0.00–60.00) | 0.66 | |
| Months since last medical consultation (median, IQR) | 111.0 (47.0–149.5) | 70.0 (21–0-130.0) | 0.06 | |
| Lost to follow-up§ | 37 (88.1%) | 98 (69.5%) | 0.02 | |
| QOL questionnaire score (median, IQR) ** | 173.5 (158.5–182.0) | 166.0 (156.0–175.5) | 0.32 |
CD celiac disease, F females, VA villous atrophy, GFD gluten-free diet, EmA endomysial antibodies, IQR interquartile range; §no medical consultations in the last 24 months
*Data not available for some patients: no HLA for 152, no pediatric GFD adherence for 19, no duodenal biopsy for 98, no EmA for 75: percentages were calculated excluding missing data points
**There was also no significant difference for any of the four domains of the questionnaire between groups
Figure 1Patients who changed their level of adherence to a gluten-free diet over time. 25/164 patients changed their GFD adherence between pediatric follow-up and first adult medical consultation (15/62 poorly adherent patients improved and 10/102 worsened their adherence). GFD adherence changed during adult follow-up in 58/183 patients (39/62 poorly adherent patients at first adult medical consultation became adherent over the long-term, while 19/121 strictly adherent patients became poorly adherent). In the long-term 141/183 patients had good GFD adherence. GFD gluten-free diet, NA not available
Multivariate analysis on predictors of successful early transition, long-term adherence to a GFD and regular long-term follow-up
| Factor | Adjusted OR (95% CI) | |
|---|---|---|
| Good GFD adherence at first adult medical consultation | 3.19 (1.53–6.66) | < 0.01 |
| Classical presentation | 2.37 (1.12–5.04) | 0.02 |
| Lost to follow-up | 0.29 (0.10–0.84) | 0.02 |
CD celiac disease, GFD gluten-free diet, OR odds ratio
Characteristics of patients in regular follow-up (at least one medical consultation in the last 24 months) and patients lost to follow-up (no medical consultation for > 24 months)
| In regular follow-up ( | Lost to follow-up ( | OR (95% CI ) | ||
|---|---|---|---|---|
| Classical presentation | 33 (68.8%) | 92 (68.1%) | 1.00 | |
| Age at diagnosis (years, median, IQR) | 10.0 (5.0–13.0) | 7.0 (1.0–13.0) | 0.15 | |
| Age at first adult medical consultation (years, median, IQR) | 18.5 (16.0- 21.5) | 21.0 (17.0–25.0) | 0.07 | |
| Good GFD adherence during pediatric follow-up* | 35 (76.1%) | 67 (56.8%) | 0.03 | 0.42 (0.17–0.94) |
| Good GFD adherence at first adult consultation | 35 (72.9%) | 86 (63.7%) | 0.29 | |
| Good GFD adherence at last contact | 43 (89.6%) | 98 (72.6%) | 0.02 | 0.31 (0.09–0.87) |
| Persistence of positive EmA * | 4 (16.0%) | 30 (36.1%) | 0.08 | |
| Persistence of VA* | 0 | 18 (27.3%) | < 0.01 | NA |
| Number of adult medical consultations (median, IQR) | 3.0 (2.0–5.75) | 2.0 (1.0–4.0) | < 0.01 | NA |
| Follow-up duration at our center (months, median, IQR) | 29.0 (0.75–111.25) | 11.0 (0.0–43.0) | 0.02 | |
| Months since last medical consultation (median, IQR) | 10.0 (4.75–17.0) | 119.0 (67.5–167.5) | NA | |
| QOL questionnaire score (median, IQR) ** | 167.0 (154.5–176.0) | 166.5 (157.75–179.25) | 0.97 | |
| Duration of disease (years, median, IQR) | 13.5 (9.00–26.25) | 24.0 (18.00–37.00) | < 0.01 |
GFD gluten-free diet, VA villous atrophy, EmA endomysial antibodies, QOL quality of life, IQR interquartile range
*Data not available for some patients: no pediatric GFD adherence for 19, no duodenal biopsy for 98, no EmA for 75: percentages were calculated excluding missing data points
**There was also no significant difference for any of the four domains of the questionnaire between groups
Figure 2Dot plot showing time since last medical consultation. Horizontal red line is set at 24 months, which was considered the cutoff for being lost to follow-up